Veracyte Inc (VCYT)
Official siteHEALTHCARE • DIAGNOSTICS & RESEARCH • NASDAQ
Market Cap: $1.96B
Last updated: Nov 17, 2026 at 11:05 AM ET
Veracyte Inc (VCYT) Stock Forecast
Analysts expect Veracyte (VCYT) to earn $1.94 per share in the fiscal year ending Dec 31, 2026, on revenue of $590.80M. Of 12 analysts, 11 rate the stock Buy or Strong Buy, 1 Hold and 0 Sell or Strong Sell, for a consensus of Buy. Over the last 30 days, 1 estimate for the fiscal year ending Dec 31, 2026 was revised up and 1 down.
Analyst Ratings
Scoring Strong Buy as 1 and Strong Sell as 5, the 12 ratings average 1.92, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 92% of the ratings.
| Rating | Analysts | Share |
|---|---|---|
| Strong Buy | 2 | 16.7% |
| Buy | 9 | 75.0% |
| Hold | 1 | 8.3% |
| Sell | 0 | 0.0% |
| Strong Sell | 0 | 0.0% |
- Consensus
- Buy
- Total analysts
- 12
Price Target
Analyst price targets are part of paid GNG plans. See plans
Annual Estimates
From the first fiscal year below to the second, the EPS consensus falls 19.1% and revenue estimates rise 7.4%.
- Fiscal year ending Dec 31, 2026
- $1.94
- EPS consensus, revenue $590.80M
- Fiscal year ending Dec 31, 2027
- $1.57
- EPS consensus, revenue $634.33M
- Next report
- Feb 22, 2027
- Estimated
EPS range
Revenue range
| Fiscal year ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | $1.94 | $1.88 to $2.00 | 9 | $590.80M | $589.50M to $592.00M | 10 |
| Dec 31, 2027 | $1.57 | $1.44 to $1.86 | 11 | $634.33M | $614.00M to $666.00M | 12 |
Quarterly Estimates
The EPS consensus falls from $0.41 for the quarter ending Dec 31, 2026 to $0.33 for the quarter ending Mar 31, 2027.
EPS range
Revenue range
| Quarter ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | $0.41 | $0.30 to $0.53 | 14 | $154.39M | $145.33M to $168.00M | 14 |
| Mar 31, 2027 | $0.33 | $0.29 to $0.41 | 9 | $148.48M | $144.57M to $154.90M | 8 |
Estimate Revisions
Across the 3 periods below, the last 30 days brought 3 upward and 3 downward EPS revisions.
| Period | Up 30 days | Down 30 days |
|---|---|---|
| Fiscal year ending Dec 31, 2026 | 1 | 1 |
| Fiscal year ending Dec 31, 2027 | 1 | 2 |
| Quarter ending Mar 31, 2027 | 1 | 0 |
EPS Trend
Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has risen 1.6% from $1.91.
| Period | Now | 7 days ago | 30 days ago | 60 days ago | 90 days ago | Change |
|---|---|---|---|---|---|---|
| Fiscal year ending Dec 31, 2026 | $1.94 | $1.91 | $1.91 | $1.91 | $1.91 | +1.9% |
| Fiscal year ending Dec 31, 2027 | $1.57 | $1.94 | $1.95 | $1.95 | $1.95 | -19.6% |
| Quarter ending Mar 31, 2027 | $0.33 | $0.44 | $0.45 | $0.44 | $0.44 | -24.9% |
Frequently Asked Questions About VCYT
What is the VCYT stock forecast?
Consensus analyst estimates put Veracyte's EPS at $1.94 for the fiscal year ending Dec 31, 2026, on revenue of $590.80M. The consensus rating from 12 analysts is Buy.
How do analysts rate VCYT stock?
Of 12 analysts covering Veracyte, 2 rate it Strong Buy, 9 Buy, 1 Hold, 0 Sell and 0 Strong Sell, for a consensus of Buy.
What EPS do analysts expect from VCYT next year?
For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is $1.94, with estimates from $1.88 to $2.00 from 9 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is $1.57, with estimates from $1.44 to $1.86 from 11 analysts.
What revenue do analysts expect from Veracyte next year?
For the fiscal year ending Dec 31, 2026, the consensus revenue estimate is $590.80M, with estimates from $589.50M to $592.00M. For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $634.33M, with estimates from $614.00M to $666.00M.
How many analysts cover VCYT?
12 analysts rate Veracyte stock, and 9 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.
VCYT pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors, Government Contracts